J&J Topamax Letter Recommends Monitoring For Decreased Sweating
Executive Summary
A warning added to Johnson & Johnson's anti-convulsant Topamax (topiramate) is in line with a label revision for Elan's anti-convulsant Zonegran stating that patients should be closely monitored for decreased sweating and increased body temperature
You may also be interested in...
Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children
FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information
Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children
FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information
J&J Topamax “Dear Doctor” Letter Advises Metabolic Acidosis Monitoring
Physicians should periodically examine Topamax (topiramate) patients for metabolic acidosis, a Johnson & Johnson "Dear Health Care Professional" letter recommends